Novocure Ltd (NVCR) General Counsel Todd Christopher Longsworth Sells 11,630 Shares

Novocure Ltd (NASDAQ:NVCR) General Counsel Todd Christopher Longsworth sold 11,630 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $24.00, for a total transaction of $279,120.00. Following the transaction, the general counsel now directly owns 16,628 shares of the company’s stock, valued at $399,072. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of Novocure Ltd (NASDAQ:NVCR) traded up $0.50 during trading hours on Thursday, hitting $21.05. 585,600 shares of the stock were exchanged, compared to its average volume of 938,487. The firm has a market cap of $1,880.00 and a price-to-earnings ratio of -25.36. Novocure Ltd has a 12 month low of $6.75 and a 12 month high of $24.15. The company has a current ratio of 5.90, a quick ratio of 5.30 and a debt-to-equity ratio of 0.83.

Several large investors have recently modified their holdings of the company. Crow Point Partners LLC bought a new stake in shares of Novocure in the 4th quarter worth approximately $120,000. Two Sigma Advisers LP bought a new stake in shares of Novocure in the 4th quarter worth approximately $211,000. Trexquant Investment LP bought a new stake in shares of Novocure in the 3rd quarter worth approximately $212,000. Legal & General Group Plc raised its holdings in shares of Novocure by 8.5% in the 2nd quarter. Legal & General Group Plc now owns 13,866 shares of the medical equipment provider’s stock worth $238,000 after purchasing an additional 1,092 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new stake in shares of Novocure in the 4th quarter worth approximately $271,000. 42.02% of the stock is owned by institutional investors.

A number of research analysts have issued reports on the stock. BidaskClub lowered shares of Novocure from a “hold” rating to a “sell” rating in a research note on Thursday. ValuEngine raised shares of Novocure from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research lowered shares of Novocure from a “buy” rating to a “hold” rating in a research note on Saturday, January 13th. Mizuho reaffirmed a “buy” rating and issued a $25.00 price target on shares of Novocure in a research note on Friday, December 1st. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novocure in a research note on Monday, November 20th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $21.13.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Week Herald and is owned by of Week Herald. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://weekherald.com/2018/02/15/todd-christopher-longsworth-sells-11630-shares-of-novocure-ltd-nvcr-stock.html.

Novocure Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply